KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Capital Expenditures (2016 - 2025)

Historic Capital Expenditures for Sarepta Therapeutics (SRPT) over the last 15 years, with Q3 2025 value amounting to $22.9 million.

  • Sarepta Therapeutics' Capital Expenditures fell 3845.37% to $22.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $136.5 million, marking a year-over-year increase of 1573.19%. This contributed to the annual value of $137.0 million for FY2024, which is 7995.43% up from last year.
  • Sarepta Therapeutics' Capital Expenditures amounted to $22.9 million in Q3 2025, which was down 3845.37% from $31.8 million recorded in Q2 2025.
  • Sarepta Therapeutics' 5-year Capital Expenditures high stood at $43.7 million for Q1 2025, and its period low was $2.2 million during Q4 2021.
  • Moreover, its 5-year median value for Capital Expenditures was $19.0 million (2023), whereas its average is $20.0 million.
  • Its Capital Expenditures has fluctuated over the past 5 years, first plummeted by 9228.94% in 2021, then surged by 26101.54% in 2022.
  • Quarter analysis of 5 years shows Sarepta Therapeutics' Capital Expenditures stood at $2.2 million in 2021, then surged by 261.02% to $8.0 million in 2022, then surged by 139.06% to $19.0 million in 2023, then skyrocketed by 100.02% to $38.1 million in 2024, then tumbled by 39.78% to $22.9 million in 2025.
  • Its Capital Expenditures stands at $22.9 million for Q3 2025, versus $31.8 million for Q2 2025 and $43.7 million for Q1 2025.